8-K
filed June 9, 2023, 7:59 PM ET
ticker CUE
CIK 0001645460
other
confidence high
sentiment neutral
materiality 0.15
Cue Biopharma announces results of 2023 Annual Meeting; all director nominees elected
Cue Biopharma, Inc.
- All 7 director nominees elected; Daniel Passeri received 11,665,042 for, 2,353,834 withheld.
- Ratification of RSM US LLP as auditor: 30,764,366 for, 105,334 against, 886,546 abstain.
- Say-on-pay approved with 11,079,655 for, 2,042,073 against, 897,148 abstain.
- Stockholders recommended annual say-on-pay votes; company will hold votes every year.
- Broker non-votes ranged from 17,737,370 across proposals.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Cue Biopharma, Inc. shareholders approved Election of directors at the 2023-06-07 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-07
Exact text from the filing
1. The Company’s stockholders elected the following nominees to the Company’s Board of Directors (the “Board”) to serve until the next annual meeting of stockholders and until their resignation or removal or their successors are duly elected and qualified, with votes cast as follows: For Withheld Broker Non-Votes Daniel R. Passeri 11,665,042 2,353,834 17,737,370 Frank Morich 9,236,907 4,781,969 17,737,370 Frederick Driscoll 10,671,595 3,347,281 17,737,370 Aaron Fletcher 11,547,019 2,471,857 17,737,370 Pamela Garzone 11,665,710 2,353,166 17,737,370 Peter A. Kiener 11,650,455 2,368,421 17,737,370 Patrick Verheyen 11,664,063 2,354,813 17,737,370
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Cue Biopharma, Inc. shareholders approved Non-binding advisory proposal on compensation of named executive officers at the 2023-06-07 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-07
Exact text from the filing
3. The Company’s stockholders approved a non-binding advisory proposal on the compensation of the Company’s named executive officers, with votes cast as follows: For Against Abstain Broker Non-Votes 11,079,655 2,042,073 897,148 17,737,370
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Cue Biopharma, Inc. shareholders approved Advisory vote on frequency of future say-on-pay votes at the 2023-06-07 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-06-07
Exact text from the filing
4. The Company’s stockholders recommended, in a non-binding advisory vote, that future advisory votes on the compensation of the Company’s named executive officers be held every one year, with votes cast as follows: One Year Two Years Three Years Abstain Broker Non-Votes 11,090,763 141,546 372,465 2,414,102 17,737,370
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Cue Biopharma, Inc. shareholders approved Ratification of appointment of RSM US LLP as independent registered public accounting firm at the 2023-06-07 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-07
Exact text from the filing
2. The Company’s stockholders ratified the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, with votes cast as follows: For Against Abstain 30,764,366 105,334 886,546
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.